Anti-CD160 Antibody (MAT 302)

Synonyms: CL1-R2
Anti-CD160 Antibody (MAT 302) (CL1-R2) 是一种靶向 CD160 的人源单克隆抗体,可阻断 CD160-HVEM 蛋白相互作用,抑制 FGF2 介导的肾小管血管生长,并诱导内皮细胞凋亡 (apoptosis),同时通过靶向新生血管上的 CD160 发挥抗血管生成和血管正常化作用,触发 NK 细胞产生 IFN-γ、TNF、IL-6,并通过 AKT/mTOR/s6k 信号通路增强 NK 细胞的葡萄糖代谢,还可使黑色素瘤小鼠的血管密度降低、使剩余肿瘤血管正常化并抑制肿瘤生长,因此可用于新生血管形成、增生性糖尿病视网膜病变、黑色素瘤的相关研究。
Anti-CD160 Antibody (MAT 302)
产品编号: MS-U05779
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Anti-CD160 Antibody (MAT 302) (CL1-R2) 是一种靶向 CD160 的人源单克隆抗体,可阻断 CD160-HVEM 蛋白相互作用,抑制 FGF2 介导的肾小管血管生长,并诱导内皮细胞凋亡 (apoptosis),同时通过靶向新生血管上的 CD160 发挥抗血管生成和血管正常化作用,触发 NK 细胞产生 IFN-γ、TNF、IL-6,并通过 AKT/mTOR/s6k 信号通路增强 NK 细胞的葡萄糖代谢,还可使黑色素瘤小鼠的血管密度降低、使剩余肿瘤血管正常化并抑制肿瘤生长,因此可用于新生血管形成、增生性糖尿病视网膜病变、黑色素瘤的相关研究。

生物实验数据

生物活性 Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160 that blocks CD160-HVEM protein interaction, inhibits FGF2-mediated tubular vascular growth, and induces endothelial cell apoptosis (apoptosis); by targeting CD160 on neovasculature, it exerts anti-angiogenic and vascular-normalizing effects, triggers NK cells to produce IFN-γ, TNF, and IL-6, and enhances NK cell glucose metabolism through the AKT/mTOR/s6k signaling pathway; it also reduces vascular density in melanoma mice, normalizes the remaining tumor vasculature, and inhibits tumor growth, making it useful for research on neovascularization, proliferative diabetic retinopathy, and melanoma.
IC50 & Target

IL-6

 

体外研究
(In Vitro)

Anti-CD160 Antibody (MAT 302) 可抑制表达 CD160 的人脐静脉内皮细胞中由 FGF2 介导的管状血管生成。
Anti-CD160 Antibody (MAT 302) 可抑制 FGF2 介导的小管生长,并在表达 CD160 的人脐静脉内皮细胞中诱导细胞凋亡。
Anti-CD160 Antibody (MAT 302) (6 µg/mL) 可特异性结合人结肠癌新生血管内皮细胞上表达的 CD160。
Anti-CD160 Antibody (MAT 302) (10 µg/mL; 1-h pre-incubation followed by 24-hour cytokine stimulation) 可显著增强 HIV 感染总 NK 细胞中 IFN-γ、GLUT1 的产生。
Anti-CD160 Antibody (MAT 302) (10 µg/mL; 30-minute incubation) 可激活 HIV 感染总 NK 细胞中的 PI3K/AKT/mTOR/s6k 信号通路,显著提高 AKT、mTOR 和 s6k 的磷酸化水平。
Anti-CD160 Antibody (MAT 302) (1-10 μg/mL; 24 h) 可抑制 FGF2 诱导的人脐静脉内皮细胞 (HUVECs) 毛细血管管形成。
Anti-CD160 Antibody (MAT 302) (10 μg/mL; 50 h) 可在 VEGF 存在的情况下诱导 HUVEC 发生凋亡,但不会诱导原代人成纤维细胞凋亡。
Anti-CD160 Antibody (MAT 302) (1-10 μg/mL; 0-50 h) 可在 HUVECs 和 SGHEC-7 内皮细胞中诱导时间依赖性凋亡。
Anti-CD160 Antibody (MAT 302) (20 μg/mL; 2 h at 4°C) 可结合 HUVEC 和 HMVEC。

Apoptosis Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs), primary human fibroblasts
Concentration: 10 μg/mL
Incubation Time: 50 h
Result: Induced apoptosis in HUVECs, resulting in a percentage of annexin V-positive cells comparable to sHLA-G1 treatment.
Showed no significant apoptosis induction in primary human fibroblasts.

Apoptosis Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs), SGHEC-7 endothelial cells
Concentration: 1 μg/mL, 10 μg/mL
Incubation Time: up to 50 h
Result: Induced time-dependent apoptosis in HUVECs and SGHEC-7 cells, with apoptotic morphology (cytoplasmic/nuclear shrinkage, phase-bright appearance, membrane blebbing) observed over the 50-hour monitoring period.
体内研究
(In Vivo)

Anti-CD160 Antibody (MAT 302) (25-100 μg;球结膜下注射;早期/联合/单药给药 2 次,晚期给药 2 次,Fab'2 方案给药 1 次) 可显著抑制兔体内由 FGF2 和 VEGF 诱导的角膜新生血管 (CNV) 形成,与 Bevacizumab (MS-Q36703) 联合使用时具有叠加效应,早期治疗可使 CNV 分级降低最高达 73%。
Anti-CD160 Antibody (MAT 302) (每眼 5 µg;玻璃体内注射;出生后第 12 天单次注射) 可有效抑制氧诱导视网膜病变小鼠模型中的病理性视网膜新生血管形成,与对照组相比,可使内皮细胞核减少约 35%,血管腔减少约 50%。
Anti-CD160 Antibody (MAT 302) (每栓 25 µg,植入时混入基质胶;每次注射 200 µg,直接注射入栓,每 2 天 1 次,持续 7 天) 可显著抑制小鼠基质胶栓实验中 FGF2 诱导的新生血管形成,与对照组相比使血红蛋白含量降低约 45%。
Anti-CD160 Antibody (MAT 302) (每次注射 500 µg;腹腔注射;自肿瘤接种日起每周 3 次) 联合 Cyclophosphamide (MS-C45849) 可使 B16 黑色素瘤的血管密度降低约 40%,使剩余肿瘤血管正常化,增强递送,并显著抑制小鼠肿瘤生长、改善其生存状况。

Animal Model: Rabbit
Dosage: 25 μg (monotherapy); 50 μg (monotherapy); 100 μg (early treatment; late treatment); 100 μg CL1-R2 Fab'2
Administration: subconjunctival; two injections (day 1 and day 3 for early treatment/combination/25-100 μg monotherapy); two injections (day 6 and day 8 for late treatment); single injection (CL1-R2 Fab'2)
Result: Reduced CNV grades by 53% (FGF2-induced) and 73% (VEGF-induced) with early 100 μg treatment compared to control IgG.
Reduced CNV grades by 57.32% with late 100 μg treatment compared to control IgG, with 45% reduction in neovessel area.
Reduced CNV by 25% with 25 μg monotherapy.
Showed equivalent potency to matching doses of bevacizumab with 50 μg and 100 μg monotherapy.
Produced additive antiangiogenic effects when combined with 25 μg bevacizumab, with increased CNV inhibition as CL1-R2 dose increased.
Inhibited CNV to a similar extent as whole CL1-R2 IgG and bevacizumab with CL1-R2 Fab'2.
Reduced corneal neovascular invasion and decreased endothelial cell proliferation (Ki-67 staining) compared to control.
Animal Model: C57BL/6J (7 days old)
Dosage: 5 µg per eye
Administration: i.v.i.; single injection on postnatal day 12
Result: Decreased the mean number of endothelial cell nuclei per section by ~35%.
Reduced the mean number of vessel lumens per section by ~50%.
Reduced avascular area, neovascular tufts, and tortuous/dilated radial vessels in flat-mounted retinas.
Decreased aberrant microvessels in retinal histology sections.
Animal Model: BALB/c (7-10 weeks old)
Dosage: 25 µg per plug; 200 µg per injection
Administration: incorporated into Matrigel at implantation; direct plug injection; every other day for 7 days
Result: Reduced hemoglobin content in Matrigel plugs by ~45%.
Showed smaller, fewer vessels in CL1-R2-treated plugs via histological analysis.
Animal Model: C57BL/6 (7-10 weeks old)
Dosage: 500 µg per injection
Administration: i.p.; three times per week starting on tumor inoculation day
Result: Reduced B16 tumor vascular density by ~40% compared with control IgG1 plus cyclophosphamide.
Showed significantly fewer intratumoral vessels at days 12, 15, and 18 post-injection.
Reduced tumor vascular area by 2.56-fold at day 14 post-implantation.
Reduced vessel fractal dimension, indicating improved hierarchical architecture.
Increased the proportion of vessels with open lumens by ~60%.
Increased pericyte coverage by >200%.
Increased perfused vessels by ~166%.
Increased tumor necrosis by ~114%.
Significantly reduced tumor growth.
Improved mouse survival to 35 days, compared with 30 days for bevacizumab or control IgG1-treated mice.

化学信息

别名 CL1-R2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础